FDA Panel Backs Novo Diabetes Drugs, With Conditions

Law360, New York (November 9, 2012, 3:26 PM EST) -- Overcoming fears of cardiovascular risks, Novo Nordisk A/S won backing Thursday for new insulin treatments Tresiba and Ryzodeg from a U.S. Food and Drug Administration advisory panel, potentially setting the stage for a new entry into the fast-growing diabetes care market.

The Endocrinologic and Metabolic Drugs Committee split 8-4 in favor of Tresiba, which consists of a long-acting insulin analog called degludec, and Ryzodeg, which contains degludec and a quick-acting insulin analog called aspart.

The committee, which voted two days after FDA staff outlined potential heart...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.